(opens in a new window)

Daniel Alexander Pryma, MD

  • Attending, Hospital at the University of Pennsylvania, Radiology Department, Philadelphia, PA
  • Member, Abramson Cancer Center Radiobiology and Imaging Research Program
  • Chief, Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Health System, Philadelphia, PA
  • Active Radiologist, Pennsylvania Hospital, Radiology Department, Philadelphia, PA
  • Active Radiologist, Penn Presbyterian Medical Center, Medical Imaging Department, Philadelphia, PA
  • Associate Director for Clinical Research , Abramson Cancer Center
  • Member, Department of Radiology Professionalism Committee, Perelman School of Medicine at the University of Pennsylvania

Department: Radiology


Contact Information

Hospital of the University of Pennsylvania
Department of Radiology
Division of Nuclear Medicine and Clinical Molecular Imaging
3400 Spruce Street
1 Donner

Philadelphia, PA 19104
Office: 215-349-5272
Fax: 215-349-5843
Email: dpryma@pennmedicine.upenn.edu


I3H Keywords

  • Cancer Immunology and Immunotherapy

Education

  • BS (Biology)
    Harvey Mudd College, 1998
  • MD (Medicine)
    Loyola University Chicago Stritch School of Medicine, 2002

Post-Graduate Training

  • Intern, Internal Medicine
    Loyola University Medical Center, 2002 - 2003
  • Chief Resident, Nuclear Medicine
    Memorial Sloan-Kettering Cancer Center, 2004 - 2005
  • Fellow, Nuclear Medicine
    Memorial Sloan-Kettering Cancer Center, 2005 - 2005
  • Resident, Nuclear Medicine
    Memorial Sloan-Kettering Cancer Center, 2003 - 2004

Certifications

  • American Board of Nuclear Medicine, 2005

Description of Clinical Expertise

PET-CT, PET, General Nuclear Medicine, Targeted Radiotherapy

Description of Research Expertise

PET, PET-CT, Targeted Radiotherapy, Radioimmunotherapy, Nuclear Oncology

Description of ITMAT Expertise

Dr. Pryma is investigating targeted systemic radiopharmaceuticals and novel molecular imaging agents for solid and hematogenous malignancies.